Clostridium Patents (Class 424/93.41)
  • Patent number: 10322154
    Abstract: Provided herein are methods of using therapeutically effective compositions of sandalwood oil to treat, prevent or reduce the recurrence of Clostridium infections.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: June 18, 2019
    Assignee: SANTALIS PHARMACEUTICALS, INC.
    Inventors: Ian Clements, Paul Castella, Corey Levenson
  • Patent number: 10280470
    Abstract: Embodiments of the invention include methods and/or compositions for analysis of samples for C. difficile infection to determine whether or not an individual is at risk for having recurrent C. difficile infection or a CDI misdiagnosis. Methods include characterization of microflora composition from the gut, wherein alterations of the microflora gut composition are indicative of recurrence of infection. Methods include analysis of nucleic acids from the gut, such as 16S rRNA as being identifying of a particular bacteria in the analysis of bacterial populations of the gut.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: May 7, 2019
    Assignee: Baylor College of Medicine
    Inventors: Tor Savidge, Emily Hollister-Branton
  • Patent number: 10178871
    Abstract: A method of preventing chicken white diarrhea and coccidiosis by providing a population of chickens an effective amount of a non-antibiotic feed, without feeding the chickens antibiotics. The feed includes a feed base and a feed additive. The feed additive can include various ingredients, including selenium and superoxide dismutase (SOD).
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 15, 2019
    Assignee: NE PLUS ENTERPRISES, LLC
    Inventors: Lijun Zhu, Lijun Qing, Qing Yang, Xiang Feng, Wuping Chen, Sixiang Chen
  • Patent number: 10086021
    Abstract: Provided are compositions comprising a bacterial strain of the genus Blautia, for use in a method of increasing the microbiota diversity and/or inducing stability of the microbiota of a subject.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 2, 2018
    Assignee: 4D Pharma PLC
    Inventors: Ian Jeffery, Fergus Shanahan, Paul O'Toole, Alex Stevenson, Imke Mulder, Helene Savignac
  • Patent number: 10086022
    Abstract: The invention provides compositions comprising one or more bacterial strains for treating or preventing visceral hypersensitivity.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 2, 2018
    Assignee: 4D Pharma PLC
    Inventors: Annick Bernalier-Donadille, Laureen Crouzet, Chloe Habouzit
  • Patent number: 10086020
    Abstract: The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 2, 2018
    Assignee: 4D Pharma PLC
    Inventors: Annick Bernalier-Donadille, Laureen Crouzet, Chloe Habouzit
  • Patent number: 10086023
    Abstract: The invention provides compositions comprising one or more bacterial strains for treating or preventing visceral hypersensitivity.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 2, 2018
    Assignee: 4D Pharma PLC
    Inventors: Annick Bernalier-Donadille, Laureen Crouzet, Chloe Habouzit
  • Patent number: 10080772
    Abstract: The invention provides compositions comprising one or more bacterial strains for use in a method of reducing the level of Enterobacteriaceae in the gastrointestinal tract.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: September 25, 2018
    Assignee: 4D Pharma PLC
    Inventors: Laureen Crouzet, Chloe Habouzit, Annick Bernalier-Donadille
  • Patent number: 10076546
    Abstract: Provided are therapeutic compositions containing combinations of bacteria, for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for use thereof.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: September 18, 2018
    Assignee: Seres Therapeutics, Inc.
    Inventors: Matthew R. Henn, David N. Cook, Toshiro K. Ohsumi, Mary-Jane Lombardo McKenzie, Kevin D. Litcofsky, Han Zhang, John Grant Aunins, David Berry
  • Patent number: 9901603
    Abstract: This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments, and methods for making, storing and using them, including storage, including long term storage, at ambient temperature. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disorder, Crohn's Disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C. difficile infection.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: February 27, 2018
    Assignee: Crestovo Holdings LLC
    Inventor: Thomas Julius Borody
  • Patent number: 9408872
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides , Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: August 9, 2016
    Assignee: Crestovo LLC
    Inventor: Thomas Julius Borody
  • Publication number: 20150147315
    Abstract: The present invention relates to a derivative bacterial strain of an avirulent, non-pathogenic Clostridium ghonii that is capable of arresting the growth of, regressing or destroying one or more solid tumours. The present invention further relates to a composition comprising the derivative bacterial strain for targeted lysis of solid tumours. The present invention further relates to methods of producing derivative strains of C. ghonii by serial culturing in tumor bearing animals.
    Type: Application
    Filed: April 29, 2013
    Publication date: May 28, 2015
    Inventor: Ming Wei
  • Patent number: 9040036
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. Coli, Gemmiger, Desulfamonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: May 26, 2015
    Inventor: Thomas Julius Borody
  • Patent number: 9028841
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: May 12, 2015
    Assignee: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Publication number: 20150104423
    Abstract: The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Applicant: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Pirjo WACKLIN, Jaana MATTO, Harri MAKIVUOKKO, Jukka PARTANEN, Janne NIKKILA
  • Publication number: 20140363397
    Abstract: There are provided novel synthetic stool preparations comprising bacteria isolated from a fecal sample from a healthy donor. The synthetic stool preparations are used for treating disorders of the gastrointestinal tract, including dysbiosis, Clostridium difficile infection and recurrent Clostridium difficile infection, prevention of recurrence of Clostridium difficile infection, treatment of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, and diverticular disease, and treatment of food poisoning such as salmonella. Methods of preparation and methods of use of the synthetic stool preparations are also provided.
    Type: Application
    Filed: September 14, 2012
    Publication date: December 11, 2014
    Applicants: QUEEN'S UNIVERSITY AT KINGSTON, UNIVERSITY OF GUELPH, KINGSTON GENERAL HOSPITAL
    Inventors: Emma Allen-Vercoe, Elaine Olga Petrof
  • Publication number: 20140341921
    Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.
    Type: Application
    Filed: November 29, 2012
    Publication date: November 20, 2014
    Applicants: The University of Tokyo, School Corporation , Azabu Veterinary Medicine Educational Institution
    Inventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
  • Publication number: 20140328813
    Abstract: Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria.
    Type: Application
    Filed: December 16, 2013
    Publication date: November 6, 2014
    Applicant: The Johns Hopkins University
    Inventors: Long DANG, Chetan BETTEGOWDA, Kenneth W. KINZLER, Bert VOGELSTEIN
  • Patent number: 8865177
    Abstract: Methods for treating a pressure sore or for preventing development of a pressure sore by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a pressure sore or to a pressure point, or to the vicinity thereof.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 21, 2014
    Assignee: Allergan, Inc.
    Inventor: Eric R. First
  • Publication number: 20140294787
    Abstract: Nutritional products having improved cohesiveness of food boluses and methods of making and using same are provided. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products and Trouton ratios of at least 6. Methods of administering such nutritional products to patients having impaired swallowing ability and/or dysphagia are also provided.
    Type: Application
    Filed: March 1, 2012
    Publication date: October 2, 2014
    Inventors: Adam Stewart Burbidge, Jan Engmann, Simina Popa Nita
  • Publication number: 20140294788
    Abstract: The present disclosure provides methods for enhancing muscle protein synthesis following physical exertion. In a general embodiment, a method for enhancing muscle protein synthesis following physical exertion is provided and includes administering to an individual a composition comprising from about 15 to about 35 g protein immediately following concurrent training. Programs for enhancing muscle adaptation resulting from concurrent training are also provided. The programs include providing a composition comprising from about 15 to about 35 g protein; and providing guidelines for consumption including a recommendation of the amount of the composition to consume immediately following concurrent training.
    Type: Application
    Filed: March 20, 2014
    Publication date: October 2, 2014
    Applicant: Nestec S.A.
    Inventors: David Mark BAILEY, Eric Scott ZALTAS, Daniel Ryan MOORE, Trent STELLINGWERFF
  • Publication number: 20140234279
    Abstract: A feed additive composition comprising a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject, which method comprising administering to a subject a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase.
    Type: Application
    Filed: January 19, 2012
    Publication date: August 21, 2014
    Applicant: DUPONT NUTRITION BIOSCIENCES APS
    Inventor: Luis Fernando Romero Millan
  • Publication number: 20140234260
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Application
    Filed: May 5, 2014
    Publication date: August 21, 2014
    Inventor: Thomas Julius BORODY
  • Publication number: 20140228212
    Abstract: Combinations suitable for agricultural use can include (I) a nematode-antagonistic biocontrol agent and (II) one or more agents selected, independently of each other, from any one of (A) to (H): (A) at least one fungicide; (B) at least one insecticide; (C) at least one synthetic nematicide; (D) bacterium of the genus Bacillus; (E) Harpin; (F) Isoflavones; (G) Plant growth regulators; and/or (H) Plant activators.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 14, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Palle Pedersen, Clifford George Watrin, Michael Oostendorp, Andre Luiz-Freitas de Oliveira
  • Publication number: 20140147425
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Application
    Filed: November 26, 2013
    Publication date: May 29, 2014
    Applicant: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Publication number: 20140116118
    Abstract: Indole-3-propionic acid as a marker and for treatment for Huntington Disease.
    Type: Application
    Filed: November 27, 2013
    Publication date: May 1, 2014
    Applicant: COUNTERPOINT HEALTH SOLUTIONS, INC.
    Inventor: Wayne R. Matson
  • Publication number: 20140112985
    Abstract: This invention relates to prophylactic and/or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its microbial content to the distal small intestine and/or colon in high quantities and density, which is a “normalized” approach to repopulate the colonic flora as a method of prevention and/or treatment of, for example, Clostridium difficile colitis.
    Type: Application
    Filed: October 22, 2012
    Publication date: April 24, 2014
    Applicant: POLONEZ THERAPEUTICS LLC
    Inventors: Wieslaw J. Bochenek, Michael L. Corrado
  • Patent number: 8680060
    Abstract: Biosurfactants produced by microbes are used to control pests. The biosurfactants can be produced by cultivating a biosurfactant-producing microbe, producing a fermentation broth, and obtaining the biosurfactant from the fermentation broth. Alternately, the biosurfactants can be produced in situ in the environment of the pests by applying a carbon substrate to the pests' environment, which permits naturally-occurring biosurfactant-producing microbes to grow and to generate the biosurfactants. The biosurfactants have pesticidal qualities, and can be used to control a variety of pests, while being biodegradable and otherwise avoiding adverse environmental effects that have often been associated with conventional synthetic pesticides.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: March 25, 2014
    Assignee: Agscitech Inc.
    Inventors: Salam M. Awada, Mohamed M. Awada, Rex S. Spendlove
  • Patent number: 8673311
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: March 18, 2014
    Assignee: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh
  • Publication number: 20140056863
    Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid eicosapentaenoic acid. It may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, ?-ketoglutarate, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 18, 2012
    Publication date: February 27, 2014
    Applicant: Nestec S.A.
    Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
  • Publication number: 20140056862
    Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and ?-ketoglutarate. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 18, 2012
    Publication date: February 27, 2014
    Applicant: Nestec S.A.
    Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
  • Publication number: 20140044685
    Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and citrulline. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, ?-keto-glutarate, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 18, 2012
    Publication date: February 13, 2014
    Applicant: NESTEC S.A.
    Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
  • Publication number: 20140037603
    Abstract: Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. Such medical conditions include infection, sepsis, malabsorption, allergy, inflammatory bowel disease, and diarrhea among others. The nutritional compositions include branched chain fatty acids and may include other functional ingredients such as, but not limited to probiotics, nucleotides and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 12, 2012
    Publication date: February 6, 2014
    Inventors: Doug Bolster, Zamzam Kabiry (Fariba) Roughead, Jennifer Mager
  • Publication number: 20140037553
    Abstract: To provide a bacterium-based microrobot which can be specifically targeted to cancer in vivo, the present invention provides a drug delivery system for cancer tissue, comprising a bacterium, and a microbead encapsulated with at least one drug, wherein biotin is bound to a surface of the bacterium and a surface of the microbead is coated with streptavidin.
    Type: Application
    Filed: July 29, 2013
    Publication date: February 6, 2014
    Applicant: Industry Foundation of Chonnam National University
    Inventors: Suk Ho Park, Jong Oh Park, Sung Jun Park, Seong Young Ko, Jung Joon Min, Seung Hwan Park
  • Publication number: 20140037604
    Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 18, 2012
    Publication date: February 6, 2014
    Applicant: NESTEC S.A.
    Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
  • Publication number: 20140037601
    Abstract: Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. The medical conditions may include wounds, mucositis among others. The nutritional compositions include branched chain fatty acids and may include other functional ingredients such as, but not limited to probiotics, nucleotides and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 12, 2012
    Publication date: February 6, 2014
    Applicant: NESTEC S.A.
    Inventor: Norman Alan Greenberg
  • Publication number: 20140037602
    Abstract: Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. The medical conditions may include allergies, autoimmune diseases, among others. The nutritional compositions include branched chain fatty acids and may include other functional ingredients such as, but not limited to probiotics, nucleotides and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 12, 2012
    Publication date: February 6, 2014
    Applicant: NESTEC S.A.
    Inventors: Doug Bolster, Norman Alan Greenberg, Jennifer Mager, Zamzam Kabiry (Fariba) Roughead
  • Publication number: 20140030241
    Abstract: Nutritional compositions having dietary nucleotides, ?-3 fatty acids and citrulline are provided. The nutritional compositions may be formulated to improve T cell function, increase arginine availability in vivo, regulate myeloid-derived suppressor cells (“MDSC”), and decrease the risk and/or severity of infection after surgery or trauma. Methods of making, using and administering such nutritional compositions to individuals in need of same are also provided. Methods for modulating the affects of MDSC's are also provided.
    Type: Application
    Filed: March 15, 2012
    Publication date: January 30, 2014
    Applicant: NESTEC S.A.
    Inventor: Norman Alan Greenberg
  • Patent number: 8613917
    Abstract: Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: December 24, 2013
    Assignee: The Johns Hopkins University
    Inventors: Long Dang, Chetan Bettegowda, Kenneth W. Kinzler, Bert Vogelstein
  • Publication number: 20130340123
    Abstract: Plant propagation material expressing soybean cyst nematode resistance can be treated with a nematode-antagonistic biocontrol agent. Use of the nematode-antagonistic biocontrol agent can reduce the rate at which soybean cyst nematode (SCN) pests acquire tolerances to pesticidal activity of soybean plants expressing SCN resistance and pesticides, and can also increase yield and pesticidal activity.
    Type: Application
    Filed: April 13, 2012
    Publication date: December 19, 2013
    Applicant: Syngenta Participations AG
    Inventors: Palle Pedersen, Clifford George Watrin, Michael Oostendorp, Andre Luiz Freitas de Oliveira
  • Publication number: 20130330307
    Abstract: A feed additive composition comprising a direct fed microbial in combination with a protease, and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for improving the subject's resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject, which method comprising administering to a subject a direct fed microbial in combination with a protease and a phytase.
    Type: Application
    Filed: January 19, 2012
    Publication date: December 12, 2013
    Applicant: DUPONT NUTRITION BIOSCIENCES APS
    Inventor: Luis Fernando Romero Millan
  • Publication number: 20130330308
    Abstract: A feed additive composition comprising a direct fed microbial (DFM) in combination with a phytase derivable from Citrobacter spp. and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject, or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure, which method comprising administering to a subject a direct fed microbial (DFM) in combination with a phytase derivable from Citrobacter spp.
    Type: Application
    Filed: January 19, 2012
    Publication date: December 12, 2013
    Applicant: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Luis Fernando Romero Millan, Luke Bernard, Peter Plumstead
  • Patent number: 8597639
    Abstract: The present invention provides an adjunctive agent and a method for lavaging the alimentary canal, which is able to reduce a dose of oral cleaning agent for lavaging the alimentary canal and is capable of realizing an excellent cleaning effect at the time of use of the oral cleaning agent. The adjunctive agent comprises butyric acid bacterium (for example, Clostridium butyricum and the like) and/or lactic acid bacterium (for example, species belonging to the genus Lactobacillus and the genus Bifidobacterium).
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: December 3, 2013
    Assignee: Miyarisan Pharmaceutical Co., Ltd.
    Inventors: Shinji Kumagai, Mamoru Tanaka
  • Patent number: 8568708
    Abstract: Clostridium novyi is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with C. novyi plus a single dose of liposomal doxorubicin. The secreted factor responsible for this phenomenon was identified and, surprisingly, proved to be a member of the lipase family. The gene encoding this protein, called liposomase, has the potential to be incorporated into diverse therapeutic methods to deliver specifically a variety of chemotherapeutic agents to tumors.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: October 29, 2013
    Assignee: The John Hopkins University
    Inventors: Ian Cheong, Shibin Zhou, Kenneth W. Kinzler, Bert Vogelstein
  • Publication number: 20130266539
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. Coli, Gemmiger, Desulfamonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Application
    Filed: June 5, 2013
    Publication date: October 10, 2013
    Inventor: Thomas Julius Borody
  • Publication number: 20130230498
    Abstract: The present invention provides for microbial compositions and methods for reducing the concentration of short-chain fatty acids in the gut as a way to reduce energy uptake and manage obesity. More specifically, the invention provides for decreasing short-chain fatty acids available for absorption in the human gut, such as acetate, using one or more of: a probiotic including a homo-acetogenic, acetate oxidizing bacterium that converts acetate to H2; a probiotic including an acetoclastic methanogen; a microbial electrolysis cell comprising a homo-acetogenic bacterium and/or an acetoclastic methanogen; a prebiotic that enhances the growth or function of acetate-scavenging microbiota; or a highly selective antibiotic that targets H2-oxidizing methanogens.
    Type: Application
    Filed: February 16, 2011
    Publication date: September 5, 2013
    Applicant: ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Bruce Rittmann, Rosa Krajmalnik-Brown, Husen Zhang, John Dibaise, Michael Crowell
  • Publication number: 20130224155
    Abstract: Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and a level of gene expression, and performing a first metabolic procedure if the genetic indicator is present, or performing an alternative second metabolic procedure if the genetic indicator is absent. One aspect discloses methods and compositions for obtaining a sample including deoxyribonucleic acids (DNA) from the subject, evaluating the DNA for an absence or presence of one or more genetic indicators and performing a first metabolic procedure or an alternative second metabolic procedure based on the absence or presence of the genetic indicator(s). Other aspects are also disclosed.
    Type: Application
    Filed: February 28, 2013
    Publication date: August 29, 2013
    Applicants: The General Hospital Corporation D/B/A Massachusetts General Hospital, ETHICON ENDO-SURGERY, INC.
    Inventors: ETHICON ENDO-SURGERY, INC., The General Hospital Corporation D/B/A Massachusetts General Hospital
  • Publication number: 20130224164
    Abstract: Compositions and methods for inhibiting Clostridium associated diseases are disclosed.
    Type: Application
    Filed: September 7, 2011
    Publication date: August 29, 2013
    Applicant: VIROPHARMA INCORPORATED
    Inventors: Walter Tatarowicz, Colin Broom
  • Publication number: 20130195820
    Abstract: The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.
    Type: Application
    Filed: July 26, 2011
    Publication date: August 1, 2013
    Applicant: SUOMEN PUNAINEN RISTI VERIPALVELU
    Inventors: Pirjo Wacklin, Jaana Matto, Harri Makivuokko, Jukka Partanen, Janne Nikkila
  • Patent number: 8460648
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: June 11, 2013
    Inventor: Thomas Julius Borody